Prostate Cancer

Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

The addition of pembrolizumab to enzalutamide did not improve survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, discussed trial data that guides when to use cabazitaxel for patients with metastatic castration-resistant prostate cancer.

In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.

Data from the PROpel study support the FDA’s approval of olaparib plus abiraterone for patients with metastatic castration-resistant prostate cancer.

The disruption of the fine-tuned androgen receptor protein multivalent interactions might contribute to AR-related human pathologies.

Investigators presented results from new studies at the 2023 ASTRO Meeting. The data showcase a new assay’s performance in predicting metastasis-free survival and distant metastasis.

Additional findings from the phase 3 LIGHTHOUSE trial support flotufolastat F 18 injection and its approval in the prostate cancer space.

The phase 1/2 trial is evaluating 64Cu/67Cu SAR-Bombesin for diagnosis and treatment of castrate resistant prostate cancer.

In an interview with Targeted Oncology, Tanya B. Dorff, MD, discussed the role of goserelin and LHRH antagonists in the ever-changing treatment landscape for patients with prostate cancer.

Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.

Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.

During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.

Findings from the largest group of patients with BRCA1/2-altered metastatic castration resistant prostate cancer are now available.

For prostate cancer awareness month, Bamidele A. Adesunloye, MD, MS, and Evan Pisick, MD, discussed recent changes and new developments that have been added to the treatment landscape.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.

No adverse events were associated with 64Cu-SAR-Bombesin treatment in patients with prostate cancer, according to findings from the phase 2 BOP trial.

In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.

Following positive results from cohorts 1 and 2 of the SECuRE trial, dosing of 64Cu/67Cu SAR-bisPSMA has begun in patients with metastatic castration-resistant prostate cancer in cohort 3.

During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.

The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.

A primary end point has been met in the phase 3 CONTACT-02 clinical trial.

At a live virtual event, Rahul Aggarwal, MD, discussed the addition of olaparib to the treatment of patients with metastatic castration-resistant prostate cancer harboring certain gene mutations.

Daniel P. Petrylak, MD, highlights data from the phase 3 KEYNOTE-921 of pembrolizumab in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer.

In the first article of a 2-part series, Mehmet A. Blien, MD, discusses where cabazitaxel fits into the treatment paradigm for patients with metastatic castration resistant prostate cancer.

Andrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.

Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.